JP2017530692A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017530692A5 JP2017530692A5 JP2017506267A JP2017506267A JP2017530692A5 JP 2017530692 A5 JP2017530692 A5 JP 2017530692A5 JP 2017506267 A JP2017506267 A JP 2017506267A JP 2017506267 A JP2017506267 A JP 2017506267A JP 2017530692 A5 JP2017530692 A5 JP 2017530692A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 68
- 239000000427 antigen Substances 0.000 claims 65
- 102000036639 antigens Human genes 0.000 claims 65
- 108091007433 antigens Proteins 0.000 claims 65
- 210000004027 cell Anatomy 0.000 claims 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims 15
- 201000010099 disease Diseases 0.000 claims 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 15
- 102000044594 Interleukin-1 Receptor Accessory Human genes 0.000 claims 11
- 101710180389 Interleukin-1 receptor accessory protein Proteins 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 11
- 230000001613 neoplastic effect Effects 0.000 claims 10
- 230000011664 signaling Effects 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 108010002352 Interleukin-1 Proteins 0.000 claims 6
- 102000000589 Interleukin-1 Human genes 0.000 claims 6
- 239000000523 sample Substances 0.000 claims 6
- 238000000338 in vitro Methods 0.000 claims 5
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 claims 4
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 4
- 102000046828 human IL1RAP Human genes 0.000 claims 4
- 210000000130 stem cell Anatomy 0.000 claims 4
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 3
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 229920001184 polypeptide Polymers 0.000 claims 3
- 102000004196 processed proteins & peptides Human genes 0.000 claims 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 206010016207 Familial Mediterranean fever Diseases 0.000 claims 2
- 208000035690 Familial cold urticaria Diseases 0.000 claims 2
- 102000018297 Immunoglobulin subtype Human genes 0.000 claims 2
- 108050007411 Immunoglobulin subtype Proteins 0.000 claims 2
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 2
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 2
- 241000282567 Macaca fascicularis Species 0.000 claims 2
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 208000014767 Myeloproliferative disease Diseases 0.000 claims 2
- 201000007224 Myeloproliferative neoplasm Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 238000001574 biopsy Methods 0.000 claims 2
- 230000009260 cross reactivity Effects 0.000 claims 2
- 208000022993 cryopyrin-associated periodic syndrome Diseases 0.000 claims 2
- 231100000433 cytotoxic Toxicity 0.000 claims 2
- 230000001472 cytotoxic effect Effects 0.000 claims 2
- 238000002405 diagnostic procedure Methods 0.000 claims 2
- 206010064570 familial cold autoinflammatory syndrome Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- 208000014829 head and neck neoplasm Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 238000001727 in vivo Methods 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000000265 leukocyte Anatomy 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 208000002874 Acne Vulgaris Diseases 0.000 claims 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 1
- 208000009746 Adult T-Cell Leukemia-Lymphoma Diseases 0.000 claims 1
- 208000016683 Adult T-cell leukemia/lymphoma Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 241000589989 Helicobacter Species 0.000 claims 1
- 208000005176 Hepatitis C Diseases 0.000 claims 1
- 208000032672 Histiocytosis haematophagic Diseases 0.000 claims 1
- 102000008100 Human Serum Albumin Human genes 0.000 claims 1
- 108091006905 Human Serum Albumin Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 201000001431 Hyperuricemia Diseases 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims 1
- 208000004575 Infectious Arthritis Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical group C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 208000004987 Macrophage activation syndrome Diseases 0.000 claims 1
- 206010027253 Meningitis pneumococcal Diseases 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- 208000034578 Multiple myelomas Diseases 0.000 claims 1
- 241000588653 Neisseria Species 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010055006 Pancreatic sarcoma Diseases 0.000 claims 1
- 206010034277 Pemphigoid Diseases 0.000 claims 1
- 241001442654 Percnon planissimum Species 0.000 claims 1
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 208000002495 Uterine Neoplasms Diseases 0.000 claims 1
- 206010046996 Varicose vein Diseases 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 206010000496 acne Diseases 0.000 claims 1
- 201000006966 adult T-cell leukemia Diseases 0.000 claims 1
- 208000026935 allergic disease Diseases 0.000 claims 1
- 230000007815 allergy Effects 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 208000000594 bullous pemphigoid Diseases 0.000 claims 1
- 201000007455 central nervous system cancer Diseases 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 235000009508 confectionery Nutrition 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 235000014113 dietary fatty acids Nutrition 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 229930195729 fatty acid Natural products 0.000 claims 1
- 239000000194 fatty acid Substances 0.000 claims 1
- 150000004665 fatty acids Chemical class 0.000 claims 1
- 208000010706 fatty liver disease Diseases 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 208000026037 malignant tumor of neck Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003068 molecular probe Substances 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- GTUJJVSZIHQLHA-XPWFQUROSA-N pApA Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@H]([C@@H]1O)O[C@H](COP(O)(O)=O)[C@H]1OP(O)(=O)OC[C@H]([C@@H](O)[C@H]1O)O[C@H]1N1C(N=CN=C2N)=C2N=C1 GTUJJVSZIHQLHA-XPWFQUROSA-N 0.000 claims 1
- 201000002526 pancreas sarcoma Diseases 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000000737 periodic effect Effects 0.000 claims 1
- 201000001245 periodontitis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000004593 pneumococcal meningitis Diseases 0.000 claims 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 201000000306 sarcoidosis Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 206010046766 uterine cancer Diseases 0.000 claims 1
- 208000027185 varicose disease Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1413913.3 | 2014-08-06 | ||
| GBGB1413913.3A GB201413913D0 (en) | 2014-08-06 | 2014-08-06 | Novel antibodies and uses thereof |
| PCT/EP2015/068208 WO2016020502A1 (en) | 2014-08-06 | 2015-08-06 | Novel antibodies and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017530692A JP2017530692A (ja) | 2017-10-19 |
| JP2017530692A5 true JP2017530692A5 (enExample) | 2018-08-30 |
| JP6827411B2 JP6827411B2 (ja) | 2021-02-10 |
Family
ID=51587804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017506267A Active JP6827411B2 (ja) | 2014-08-06 | 2015-08-06 | 新規の抗体及びその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10100119B2 (enExample) |
| EP (1) | EP3193926B1 (enExample) |
| JP (1) | JP6827411B2 (enExample) |
| KR (1) | KR20170039685A (enExample) |
| CN (1) | CN107074946B (enExample) |
| AU (1) | AU2015298852A1 (enExample) |
| BR (1) | BR112017002342A2 (enExample) |
| CA (1) | CA2955056A1 (enExample) |
| GB (1) | GB201413913D0 (enExample) |
| MX (1) | MX2017001599A (enExample) |
| WO (1) | WO2016020502A1 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| GB201403875D0 (en) | 2014-03-05 | 2014-04-16 | Cantargia Ab | Novel antibodies and uses thereof |
| US11708608B2 (en) | 2014-11-10 | 2023-07-25 | Genentech, Inc. | Therapeutic and diagnostic methods for IL-33-mediated disorders |
| US10093730B2 (en) | 2014-11-10 | 2018-10-09 | Genentech, Inc. | Anti-interleukin-33 antibodies and uses thereof |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| WO2017181790A1 (zh) * | 2016-04-19 | 2017-10-26 | 南京中硼联康医疗科技有限公司 | 用于消除β淀粉样蛋白沉积斑块的中子捕获治疗系统 |
| EP3241845A1 (en) | 2016-05-06 | 2017-11-08 | MAB Discovery GmbH | Humanized anti-il-1r3 antibodies |
| CA3084459A1 (en) | 2016-10-16 | 2018-04-19 | Cellerant Therapeutics, Inc. | Anti-il1-rap antibodies |
| MX389083B (es) | 2016-12-01 | 2025-03-20 | Regeneron Pharma | Anticuerpos anti-pd-l1 radiomarcados para imagenes de inmuno-pet. |
| MX2019009565A (es) | 2017-02-10 | 2020-02-24 | Regeneron Pharma | Anticuerpos anti-lag3 radiomarcados para la obtención de imágenes mediante inmuno-pet. |
| EP3401332A1 (en) | 2017-05-08 | 2018-11-14 | MAB Discovery GmbH | Anti-il-1r3 antibodies for use in inflammatory conditions |
| US11248054B2 (en) | 2017-06-12 | 2022-02-15 | Bluefin Biomedicine, Inc. | Anti-IL1RAP antibodies and antibody drug conjugates |
| US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| CN111246882A (zh) * | 2017-08-01 | 2020-06-05 | 希望之城 | 抗il1rap抗体 |
| EP3489259A1 (en) * | 2017-11-23 | 2019-05-29 | Etablissement Français du Sang | Anti-il-1rap-car-t cells and their use |
| JP2021513969A (ja) * | 2018-02-14 | 2021-06-03 | イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ | Ｔｒｅｍまたはｔｒｅｍｌタンパク質を調節するための組成物および使用方法 |
| WO2020035577A1 (en) | 2018-08-16 | 2020-02-20 | Cantargia Ab | Anti-il1rap antibody compositions |
| TW202021618A (zh) | 2018-08-17 | 2020-06-16 | 美商２３與我有限公司 | 抗ｉｌ１ｒａｐ抗體及其使用方法 |
| JP2022521428A (ja) | 2019-02-25 | 2022-04-07 | ザ・ユニバーシティ・オブ・シカゴ | 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物 |
| WO2021148884A1 (en) * | 2020-01-24 | 2021-07-29 | Tychan Pte. Ltd. | Anti-wuhan coronavirus antibodies |
| TW202144410A (zh) | 2020-03-13 | 2021-12-01 | 美商建南德克公司 | 抗介白素－３３抗體及其用途 |
| JP2023521174A (ja) * | 2020-04-10 | 2023-05-23 | シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） | インターロイキン１受容体アクセサリータンパク質に特異的なバインダーおよびキメラ抗原受容体 |
| PE20231575A1 (es) | 2020-09-14 | 2023-10-04 | Ichnos Sciences SA | Anticuerpos que se unen a il1rap y usos de estos |
| JP2024500847A (ja) | 2020-12-18 | 2024-01-10 | センチュリー セラピューティクス，インコーポレイテッド | 適合可能な受容体特異性を有するキメラ抗原受容体システム |
| CA3220913A1 (en) | 2021-05-21 | 2022-11-24 | Leo Pharma A/S | Anti il-1 receptor accessory protein antibodies |
| EP4562155A2 (en) * | 2022-07-25 | 2025-06-04 | Interius Biotherapeutics, Inc. | Mutated polypeptides, compositions comprising the same, and uses thereof |
| AR130550A1 (es) | 2022-09-21 | 2024-12-18 | Sanofi Biotechnology | Anticuerpo anti-il-1r3 humanizado y métodos de uso |
| CN120813608A (zh) * | 2023-02-09 | 2025-10-17 | 希望之城公司 | 抗il1rap抗体及其变体 |
| CN120882427A (zh) * | 2023-03-24 | 2025-10-31 | 派拉冈医疗公司 | 结合FcRn的Fc片段和使用方法 |
| WO2025126157A1 (en) * | 2023-12-15 | 2025-06-19 | Advesya | Anti-il-1rap binding domains and antibody-drug conjugates thereof |
| WO2025201513A1 (zh) * | 2024-03-29 | 2025-10-02 | 珠海丹序生物制药有限公司 | 抗il1rap抗体及其用途 |
| WO2026022232A1 (en) | 2024-07-24 | 2026-01-29 | Almirall, S.A. | Il-1rap inhibitor for treating or preventing hidradenitis suppurativa |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| SE459005B (sv) | 1985-07-12 | 1989-05-29 | Aake Rikard Lindahl | Saett att framstaella sfaeriska polymerpartiklar |
| PE64396A1 (es) | 1995-01-23 | 1997-01-28 | Hoffmann La Roche | Proteina accesoria del receptor de la interleucina 1 |
| CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
| US20030215453A1 (en) | 2002-05-14 | 2003-11-20 | Dedera Douglas A. | Methods of therapy and diagnosis using immunotargeting of cells expressing VpreB1 protein |
| US7960512B2 (en) | 2003-01-09 | 2011-06-14 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US20060019256A1 (en) | 2003-06-09 | 2006-01-26 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| GB0316294D0 (en) | 2003-07-11 | 2003-08-13 | Polytherics Ltd | Conjugated biological molecules and their preparation |
| ES2426816T3 (es) | 2004-08-04 | 2013-10-25 | Mentrik Biotech, Llc | Regiones Fc variantes |
| WO2009091547A1 (en) | 2008-01-15 | 2009-07-23 | The Board Of Trustees Of The Leland Stanford Junior University | Markers of acute myeloid leukemia stem cells |
| WO2009120903A2 (en) | 2008-03-26 | 2009-10-01 | Cellerant Therapeutics, Inc. | Cytokine receptors associated with myelogenous haematological proliferative disorders and uses thereof |
| GB2472856B (en) | 2009-08-21 | 2012-07-11 | Cantargia Ab | IL1-RAP modulators and uses thereof |
| WO2012098407A1 (en) | 2011-01-19 | 2012-07-26 | Cantargia Ab | Anti - il1rap antibodies and their use for treating human |
| CN103077969B (zh) | 2011-10-26 | 2016-03-30 | 中国科学院微电子研究所 | 一种mos器件及其制造方法 |
| CN108026172B (zh) | 2015-06-26 | 2022-04-29 | 赛诺菲生物技术公司 | 单克隆抗il-1racp抗体 |
| JP2018534933A (ja) | 2015-11-02 | 2018-11-29 | ヤンセン ファーマシューティカ エヌ．ベー． | 抗ｉｌ１ｒａｐ抗体、ｉｌ１ｒａｐとｃｄ３を結合する二重特異性抗原結合分子、及びその使用 |
-
2014
- 2014-08-06 GB GBGB1413913.3A patent/GB201413913D0/en not_active Ceased
-
2015
- 2015-08-06 AU AU2015298852A patent/AU2015298852A1/en not_active Abandoned
- 2015-08-06 BR BR112017002342-3A patent/BR112017002342A2/en not_active Application Discontinuation
- 2015-08-06 CN CN201580042011.9A patent/CN107074946B/zh active Active
- 2015-08-06 EP EP15747487.5A patent/EP3193926B1/en active Active
- 2015-08-06 MX MX2017001599A patent/MX2017001599A/es unknown
- 2015-08-06 US US15/501,710 patent/US10100119B2/en active Active
- 2015-08-06 KR KR1020177004417A patent/KR20170039685A/ko not_active Withdrawn
- 2015-08-06 CA CA2955056A patent/CA2955056A1/en not_active Abandoned
- 2015-08-06 WO PCT/EP2015/068208 patent/WO2016020502A1/en not_active Ceased
- 2015-08-06 JP JP2017506267A patent/JP6827411B2/ja active Active
-
2018
- 2018-08-22 US US16/109,017 patent/US10562971B2/en active Active